NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, Humira induced clinical remission…
GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above
London UK, Philadelphia USA April 26, 2019 — GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of Benlysta (belimumab), a B-lymphocyte stimulator (BLyS)-specific inhibitor, in children with lupus from as young as five years of…